- Home
- VLTO vs BIIB Comparison
VLTO vs BIIB Comparison
Compare VLTO & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VLTO
- BIIB
- Stock Information
- Founded
- VLTO 2023
- BIIB 1978
- Country
- VLTO United States
- BIIB United States
- Employees
- VLTO N/A
- BIIB N/A
- Industry
- VLTO Electrical Products
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- VLTO Industrials
- BIIB Health Care
- Exchange
- VLTO Nasdaq
- BIIB Nasdaq
- Market Cap
- VLTO 25.1B
- BIIB 25.1B
- IPO Year
- VLTO N/A
- BIIB 1991
- Fundamental
- Price
- VLTO $106.53
- BIIB $157.78
- Analyst Decision
- VLTO Buy
- BIIB Buy
- Analyst Count
- VLTO 12
- BIIB 25
- Target Price
- VLTO $108.27
- BIIB $258.57
- AVG Volume (30 Days)
- VLTO 1.3M
- BIIB 1.6M
- Earning Date
- VLTO 02-04-2025
- BIIB 10-30-2024
- Dividend Yield
- VLTO 0.34%
- BIIB N/A
- EPS Growth
- VLTO N/A
- BIIB 10.05
- EPS
- VLTO 3.24
- BIIB 11.06
- Revenue
- VLTO $5,136,000,000.00
- BIIB $9,607,500,000.00
- Revenue This Year
- VLTO $5.54
- BIIB N/A
- Revenue Next Year
- VLTO $5.40
- BIIB N/A
- P/E Ratio
- VLTO $32.88
- BIIB $14.26
- Revenue Growth
- VLTO 3.11
- BIIB N/A
- 52 Week Low
- VLTO $73.91
- BIIB $153.62
- 52 Week High
- VLTO $115.00
- BIIB $268.30
- Technical
- Relative Strength Index (RSI)
- VLTO 50.64
- BIIB 33.43
- Support Level
- VLTO $105.09
- BIIB $158.44
- Resistance Level
- VLTO $107.95
- BIIB $162.62
- Average True Range (ATR)
- VLTO 1.69
- BIIB 3.19
- MACD
- VLTO 0.21
- BIIB 0.90
- Stochastic Oscillator
- VLTO 64.12
- BIIB 35.65
About VLTO Veralto Corp
Veralto Corp is company which is a provider of essential technology solutions that safeguard many of the world's most vital resources. The company operates in two segments such as Water Quality and Product Quality & Innovation. Through WQ segment it improves the quality and reliability of water through leading brands including Hach, Trojan Technologies and ChemTreat. Through PQI segment it promotes consumer trust in products and help enable product innovation through brands including Videojet, Linx, Esko, X-Rite and Pantone.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.